Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 11,408 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Quercetin, Acarbose, placebo; Dietary Supplement · Drug
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Autism Spectrum Disorder, Neurodevelopmental Disorders
Interventions: Remaking Recess, TEAM; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 5 Years and older
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Eugene, Oregon • Seattle, Washington

Conditions: Chronic Hepatitis B
Interventions: Tenofovir DF, FTC, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Conditions: Metabolism
Interventions: Visbiome; Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Meningitis, Neoplasms
Interventions: Gemcitabine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 5
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania • Houston, Texas + 1 more

Conditions: Acute Respiratory Distress Syndrome
Interventions: Aspirin, Lactose powder; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Stanford, California • Bridgeport, Connecticut • Gainsville, Florida + 11 more

Conditions: Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
Interventions: PF-08634404, Bevacizumab, Chemotherapy; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 254
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more

Conditions: Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Digital Health Coaching Program, Fitbit; Behavioral · Device
Lead sponsor: Pack Health; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Suicide, Suicide, Attempted, Suicidal Ideation
Interventions: DBT Online Program; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 165
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more

Conditions: Liposarcoma, Leiomyosarcoma
Interventions: Yondelis, Dexamethasone; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 20
States / cities: Los Angeles, California • Aurora, Colorado • Coeur d'Alene, Idaho + 17 more

Conditions: Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
Interventions: IV ICT01; Biological
Lead sponsor: ImCheck Therapeutics, an Ipsen company; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Gilbert, Arizona • Duarte, California • New Haven, Connecticut + 5 more

Conditions: Depressive Disorder, Major
Interventions: orvepitant, placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Arcadia, California + 14 more

Conditions: Smallpox
Interventions: MVA Smallpox Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 523 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 4 more

Conditions: Multiple Myeloma, Plasma Cell Myeloma, Precancerous Condition
Interventions: cytogenetic analysis, microarray analysis, biologic sample preservation procedure, laboratory biomarker analysis; Genetic · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 69
States / cities: Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 41 more

Conditions: Vasomotor Rhinitis
Interventions: Cold-dry air provocation, Warm-moist air provocation; Other
Lead sponsor: Associated Scientists to Help Minimize Allergies; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Right to Left Shunt, Patent Foramen Ovale, Atrial Septal Defect
Interventions: Flow Detection System; Device
Lead sponsor: Cardiox Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Colorectal Cancer
Interventions: mt-sDNA 2.0 screening test, FIT test, Colonoscopy; Diagnostic Test · Procedure
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 40 Years and older
Enrollment: 26,758 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 195
States / cities: Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 161 more

Conditions: Recurrent Malignant Glioma
Interventions: IL13-PE38QQR; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 3 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Contraception, Female Contraception
Interventions: DR-102; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 2,858 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 52
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: Dementia With Lewy Bodies (DLB)
Interventions: Neflamapimod; Drug
Lead sponsor: EIP Pharma Inc; Industry
Eligibility: 55 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 22
States / cities: La Jolla, California • Santa Monica, California • Aurora, Colorado + 18 more

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more

Conditions: Antibody-mediated Rejection
Interventions: Clazakizumab, Physiologic saline solution; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more

Search by objective public record fields.

Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.

School-based Paraeducator Education for Engagement at Recess

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Impact of Probiotics on Drug, Vitamin, and Hormone Metabolism

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine

LIPS-A: Lung Injury Prevention Study With Aspirin

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

Now Matters Now: An Online Suicide Prevention Program

Islet Transplantation for Type 1 Diabetes

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

First-in-Human Study of ICT01 in Patients With Advanced Cancer

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation

Right to Left Cardiac Shunt Detection

Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients